C4 Therapeutics vs Celsius Which Is a Better Investment?

C4 Therapeutics and Celsius stocks are two companies in the biotechnology and wellness sectors, respectively, that have been gaining attention from investors in recent years. C4 Therapeutics specializes in developing targeted protein degradation therapies for various diseases, while Celsius focuses on creating innovative beverages and supplements to support an active lifestyle. Both companies have shown promising growth potential in their respective fields, attracting interest from both individual and institutional investors looking for opportunities in the rapidly evolving healthcare and wellness industries.

C4 Therapeutics or Celsius?

When comparing C4 Therapeutics and Celsius, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between C4 Therapeutics and Celsius.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. C4 Therapeutics has a dividend yield of -%, while Celsius has a dividend yield of -%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. C4 Therapeutics reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%. On the other hand, Celsius reports a 5-year dividend growth of 0.00% year and a payout ratio of 13.56%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with C4 Therapeutics P/E ratio at -2.84 and Celsius's P/E ratio at 35.23. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. C4 Therapeutics P/B ratio is 1.24 while Celsius's P/B ratio is 16.89.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, C4 Therapeutics has seen a 5-year revenue growth of -0.68%, while Celsius's is 15.30%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with C4 Therapeutics's ROE at -42.45% and Celsius's ROE at 20.74%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are $4.02 for C4 Therapeutics and $29.32 for Celsius. Over the past year, C4 Therapeutics's prices ranged from $1.76 to $11.88, with a yearly change of 575.00%. Celsius's prices fluctuated between $25.23 and $99.62, with a yearly change of 294.85%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.